White & Case (Brussels)

Assimakis Komninos

White & Case (Brussels)
Lawyer (Partner)

Assimakis advises on questions of EU and Greek competition law, EU business regulation, international arbitration, litigation and private international law. He has argued both of the only two competition preliminary reference cases to the European Court of Justice (ECJ) from Greece. His practice focuses on complex cases of abuse of dominance, restrictive agreements and merger notifications, and he represents clients before the European Courts, the European Commission, national competition authorities, national courts and international arbitration tribunals. Clients look to Assimakis for his proven track record and his ability to combine quietly resolving the most sensitive and complex investigations with aggressively litigating to achieve the necessary results. Chambers Global 2020 notes that he has "a solid theoretical background, which means he can handle different complex cases", while Legal 500 2020 lauds him for "his professionalism, proactive mentality and good communication ethos." Assimakis has acted before the ECJ in Syfait v. GlaxoSmithKline and Lélos v. GlaxoSmithKline (parallel trade of pharmaceuticals - abuse of dominance), and in GlaxoSmithKline Services v. Commission (parallel trade of pharmaceuticals - Article 101). He has also been involved before the EU General Court in Microsoft v. Commission (compulsory licensing of interoperability information), GlaxoSmithKline Services v. Commission (parallel trade of pharmaceuticals - application of Article 101), Chalkor Metal Works v. Commission (copper plumbing tubes), Public Power Corporation v. Commission (Greek lignites), EAEPC v. Commission (rejection of a complaint), representing GlaxoSmithKline, and Google v. Commission (Google Shopping), representing the Computer & Communications Industry Association (CCIA). He also successfully represented Aegean Airlines in Aegean/Olympic II, which resulted in the European Commission clearing the deal in a Phase II proceeding. This was the first time that the Commission cleared a merger after it had previously prohibited it. Assimakis has represented clients with excellent results in proceedings before the Albanian, Croatian, Cypriot, French, Greek, Kosovo, Romanian, Russian and Slovenian competition authorities and Belgian, Bulgarian, Cypriot, French, Greek, Latvian, Spanish and Russian courts. He has particular experience in arbitration cases involving competition issues, and in private antitrust litigation cases in national courts. Assimakis is a former Commissioner and Member of the Board of the Hellenic Competition Commission (HCC). Assimakis is currently a visiting fellow of the Centre for Law and Governance in Europe at University College London (UCL) and a member of the Executive Committee of the Global Competition Law Centre (GCLC) at the College of Europe. He is a prolific writer on legal matters and often gives speeches and seminars on EU competition law, arbitration and Greek law, and is a non-governmental advisor to the International Competition Network (ICN).

Distinctions

Auteurs associés

White & Case (Brussels)
White & Case (Washington)
White & Case (New York)
White & Case (Washington)
White & Case (New York)

Vidéos

Assimakis Komninos
Assimakis Komninos 28 octobre 2016 New York
Assimakis Komninos & Jacquelyn Maclennan, White & Case
Assimakis Komninos 25 mars 2014 Washington DC

Articles

19738 Bulletin

Peter Citron, Tilman Kuhn, Assimakis Komninos, James Killick, Jérémie Jourdan The EU Court of Justice dismisses the appeals of several manufacturers of medicines involved in an agreement seeking to delay the marketing of the generic antidepressant citalopram (Lundbeck)

638

On 25 March 2021, the European Court of Justice ("ECJ") dismissed all the appeals against the European Commission’s decision to fine Lundbeck and several other companies for entering into anti-competitive patent settlement agreements. The judgments largely repeat the position taken by the ECJ (...)

James Killick, Assimakis Komninos, Aqeel Kadri The UK Court of Appeal upholds the Competition Appeal Tribunal’s quashing of the Competition Authority’s decision against pharmaceutical undertakings who had allegedly abused their dominant position by pricing their epilepsy drug unfairly (Pfizer / Flynn)

258

On 10 March 2020 the Court of Appeal upheld the Competition Appeal Tribunal’s (CAT) quashing of the Competition and Markets Authority’s (CMA) decision that Pfizer and Flynn Pharma (Flynn) had abused their dominant positions in the market by pricing their epilepsy drug unfairly. Among other (...)

James Killick, Assimakis Komninos, Strati Sakellariou-Witt The UK Competition Authority closes its investigation into an allegedly abusive discount scheme in the pharmaceutical sector (Remicade)

562

This article has been nominated for the 2020 Antitrust Writing Awards. Click here to learn more about the Antitrust Writing Awards. The CMA Remicade decision : discount schemes and abuse of dominance – effects matter !* Summary On 14 March 2019, the UK Competition and Markets Authority (CMA) (...)

Assimakis Komninos, James Killick The EU Court of Justice dismisses the Commission’s appeal against the annulment of its decision to prohibit a merger in the parcel delivery market (UPS / TNT)

591

This article has been nominated for the 2020 Antitrust Writing Awards. Click here to learn more about the Antitrust Writing Awards. EU Court confirms the need for transparency and full disclosure of economic analyses in EU merger cases (UPS/TNT)* On 16 January 2019, the Court of Justice of (...)

Assimakis Komninos, James Killick The UK Competition Appeal Tribunal announces its provisional judgment in an appeal against the Competition Authority’s infringement decision in an excessive price case (Pfizer / Flynn)

533

I. Introduction In the last couple of years, there has been a trend for antitrust watchdogs around the world to investigate excessive pricing, especially in the pharmaceutical sector. Last year, the European Commission opened its first investigation into excessive pricing in the pharmaceutical (...)

Assimakis Komninos, James Killick, Jacquelyn MacLennan, Jérémie Jourdan, Strati Sakellariou-Witt, Jan Jeram, Axel P. Schulz The EU Court of Justice endorses an effects-based assessment of rebates (Intel)

771

This article has been nominated for the 2018 Antitrust Writing Awards. Click here to learn more about the Antitrust Writing Awards. On 6 September 2017, the Court of Justice of the European Union ("CJEU" or "Court") essentially held in Intel that the European Commission ("Commission") cannot (...)

Assimakis Komninos, Ian Forrester, James Killick The EU Court of Justice holds that parent companies may be fined for repeated infringements even without being an addressee of the earlier decisions (Versalis)

813

On 5 March 2015, the European Court of Justice (CoJ) handed down its judgment in Versalis , concerning the increasing of fines for antitrust infringements where a company is found to be a repeat offender. The judgment raises important questions about the respect for the rights of defence in EU (...)

Assimakis Komninos, Ian Forrester, Jacquelyn MacLennan, Kai Struckmann, Mark D. Powell, Pontus Lindfelt The European Commission adopts a package on private damages actions in antitrust cases

248

This article has been nominated for the 2014 Antitrust Writing Awards. Click here to learn more about the Antitrust Writing Awards. Summary On 11 June 2013, the European Commission (“Commission”) adopted a proposal for a directive on how citizens and companies can bring damages claims under EU (...)

Assimakis Komninos The EU Court of Justice rules that the Greek Competition Authority is not a “court or tribunal” in the meaning of Art. 234 EC and therefore can not apply for an ECJ preliminary ruling (Syfait / GlaxoSmithKline)

10588

On 31 May 2005 the European Court of Justice (ECJ) delivered its judgment in Case C-53/03, Syfait and others v. GlaxoSmithKline AEVE and GlaxoSmithKline plc (“Syfait”), which raises the question of whether a dominant pharmaceutical undertaking is under a duty to supply unlimited quantities of (...)

35610 Revue

Sir David Edward, Jacquelyn MacLennan, Assimakis Komninos A Scot Without Borders Liber Amicorum (Volume II), Ian Forrester, Sir David EDWARD, Jacquelyn MACLENNAN et Assimakis KOMNINOS

56

Cette rubrique Livres recense et commente les ouvrages et autres publications en droit de la concurrence, droit & économie de la concurrence et en droit de la régulation. Une telle recension ne peut par nature être exhaustive et se limite donc à présenter quelques publications récentes dans ces (...)

Agisilaos Karpetas, Assimakis Komninos, Frédéric Jenny, Knut Fournier, Michèle Carpagnano La réparation des dommages concurrentiels dans les systèmes juridiques étrangers (La réparation des dommages concurrentiels en France et en Europe : État des lieux et changements à venir, Paris, 13 mai 2014)

906

La première table-ronde de la conférence qui s’est tenue le 13 mai 2014 à Paris sur le thème de la réparation des dommages concurrentiels était dédiée aux dommages concurrentiels dans les systèmes juridiques étrangers. Michele CARPAGNANO Professeur, Université de Trente Codirecteur, Osservatorio (...)

Antonello Schettino, Assimakis Komninos, Christopher Brown, Ekaterina Rousseva, Gianluca Faella, Victoria Mertikopoulou Efficiency defences in abuse of dominance cases

1896

L’existence et l’application de la soi-disant "exception d’efficience" de l’article 102 du TFUE ont fait l’objet de grandes discussions ces dernières années. Le document d’orientation de 2009 a donné un nouvel essor à la notion. Les articles réunis dans ce tendances donnent le point de vue de l’Union (...)

Assimakis Komninos, David Bosco, Frédéric Marty, Hans Zenger, Strati Sakellariou-Witt Le test de l’opérateur aussi efficace : Une nouvelle ère ?

2907

La Commission européenne voit dans le « test de l’opérateur aussi efficace » un test général applicable aux stratégies tarifaires des entreprises dominantes. Les contributions à ce Tendances présentent ce test dans les différents domaines où l’on le rencontre. Le sujet a d’autant plus d’intérêt que la (...)

Assimakis Komninos, Florence Ninane, Francesco Rosati, Geoffrey D. Oliver, Hendrik Bourgeois, Ioannis Lianos, James Killick, Johanne Peyre, Niamh McCarthy, Philippe Choné The EU guidance on exclusionary abuses : A step forward or a missed opportunity ?

6871

What does the Commission’s recent Communication on enforcement of Article 82 EC mean for companies ? Does it make enforcement more predictable ? Does the greater use of economic concepts reduce the risk that intense competition on the merits by the part of a dominant firm will be considered (...)

Assimakis Komninos, Jose Luis Buendia, Pascal Berghe, Patrick Rey, Robert Kovar, Thierry Dahan Importations parallèles : Comment concilier intérêt du consommateur et intégration du marché communautaire ?

7236

Cette deuxième table-ronde du colloque "Quel avenir pour les restrictions verticales ?" (Paris, 23 mai 2008) est dédiée aux questions posées par les importations parallèles. Les récentes affaires en matère de produits pharmaceutiques ont souligné l’importance des enjeux et la difficulté de (...)

Assimakis Komninos The EU White Paper for damages actions : A first appraisal

6155

The European Commission has published early April 2008 its White Paper on damages actions for antitrust violations. The White Paper makes a number of important specific proposals with the aim to facilitate civil antitrust claims for damages in Europe that will certainly create a lot of (...)

Assimakis Komninos, Ian Forrester Agenda de Lisbonne et droit de la concurrence

5567

La Commission européenne tend de plus en plus à faire référence aux objectifs de l’Agenda de Lisbonne, et plus particulièrement à la compétitivité des entreprises européennes dans ses discours sur la politique communautaire de concurrence. L’Agenda de Lisbonne est présenté comme l’objectif prioritaire de (...)

Livres

Envoyer un message